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A B S T R A C T   
Background: In this study, the ability of antimicrobial photodynamic therapy (aPDT) as a treatment approach and 
adjuvant therapy using curcumin-poly (lactic-co-glycolic acid) nanoparticles (Cur@PLGA-NPs) to inactivate 
Coronavirus disease 2019 (COVID-19) in plasma was investigated. Furthermore, to verify whether the quality 
requirement of aPDT-treated plasma is acceptable, the differences of the levels of clotting factors, total plasma 
proteins, and anti-A and/or anti-B antibodies titrations in plasma of patient before and after aPDT treatment 
were investigated. 
Materials and Methods: Cur@PLGA-NPs was synthesized using Electrospinning process and characterized by 
different analysis including Scanning Electron Microscope (SEM), Transmission Electron Microscope (TEM), and 
Fourier Transform Infrared (FTIR) spectroscopy assays. The presence of the SARS-CoV-2 in the plasma samples of 
patients suspected of having COVID-19 was confirmed by real-time reverse transcription-polymerase chain re-
action (RT-PCR) assay. Then, the treated plasma samples with Cur@PLGA-NPs plus blue laser were exposed to 
Vero cells. Eventually, cell cytotoxicity and apoptotic effects of treated Vero cells were evaluated. Levels of 
clotting factors including prothrombin time (PT) and activated partial thromboplastin time (APTT), total plasma 
proteins, and anti-A and/or anti-B antibodies measurements were performed using the coagulometer, method of 
Bradford, and titration procedure, respectively. 
Results: The presence of SARS-CoV-2 was positive in 84.3 % of samples. Different concentrations of Cur@PLGA- 
NPs (3, 5, 7, and 10 % wt.), the irradiation times of blue laser (1, 3, and 5 min), and aPDT with the maximum 
dosed of blue laser light (522.8 J/cm2) plus 10 % wt. Cur@PLGA-NPs had no cytotoxicity. Although there were 
significant cell degradation and apoptotic effects in treated Vero cells with treated plasma using 10 % wt. 
Cur@PLGA-NPs, and a blue laser at an energy density of 522.8 J/cm2, no visible changes in cells and apoptosis 
were observed following aPDT. Total plasma protein content, PT, APTT, and anti-A and/or anti-B antibodies 
titers showed no significant changes (P > 0.05 for all comparisons) in treated plasma as compared to untreated 
plasma. 
Conclusion: aPDT exhibited in vitro anti-COVID-19 activities in the treated plasma containing SARS-COV-2 
without Vero cell apoptosis and any adverse effects on plasma quality in aPDT-exposed plasma.   
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1. Introduction 
Coronavirus disease 2019 (COVID-19) is a contagious respiratory 
illness caused by a new strain of coronavirus named Severe Acute Res-
piratory Syndrome Coronavirus-2 (SARS-CoV-2). The first case of 
COVID-19 was identified in Wuhan, Hubei province, China, in December 
2019. It has since rapidly spread worldwide, resulting in an ongoing 
pandemic [1]. SARS-CoV-2 is an enveloped virus with a positive sense, 
single-stranded RNA genome [2]. It can enter the host cells by the 
transmembrane spike (S) glycoprotein. This glycoprotein contains a 
receptor-binding domain (RBD) that specifically recognizes its host re-
ceptor angiotensin-converting enzyme 2 (ACE2). By inhibiting RBD 
binding to its receptor can be prevented from the entry of the 
SARS-CoV-2 to the host cells and reduced the proliferation and patho-
genicity of the virus [3]. SARS-CoV-2 is able to invade and affect the 
upper respiratory tract (throat, nose, and sinuses) and the lower respi-
ratory tract (lungs). The lungs are the main organ affected by 
SARS-CoV-2 because the virus accesses type II alveolar cells of the lungs 
via ACE2, which is most abundant in these pneumocytes. As the alveolar 
disease progresses, SARS-CoV-2 may also enter the bloodstream from 
the lungs, and systemic disease might develop as well as death may 
follow [3]. 
According to the literature, there are few antiviral drugs for the 
treatment of COVID-19. Primary and secondary bio-molecules have 
recently been introduced for optical and electrical diagnosis as well as 
monitoring of SARS-CoV-2 infections using the spectroscopy, fluores-
cence, and conductivity-based techniques [4]. 
It has been revealed that human airway epithelial cells highly ex-
press the receptors for SARS-CoV-2, including transmembrane serine 
proteinase 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2), 
but they are expensive and do not proliferate indefinitely. However, 
some infinitely proliferating cell lines, including Calu-3, Caco-2, Huh7, 
and HEK293 T have been used in SARS-CoV-2 infection experiments. 
These cell lines generate low titer of infectious SARS-CoV-2 and do not 
exactly mimic human physiological systems and complexity. Regarding 
this limitation, valuable information about infection and replication of 
SARS-CoV-2 can be learned from studies using these cell lines. Among 
the several infinitely proliferating cell lines, a cell line, such as Vero 
cells, that can easily replicate and isolate higher titer virus is essential for 
efficient SARS-CoV-2 infection experiments. Despite the primary human 
airway epithelial cells, Vero cells do not produce interferon (IFN) when 
infected with viruses including SARS-CoV-2. The IFN deficiency permits 
SARSCoV-2 to replicate efficiently in Vero cells and has given a high titer 
of the virus [5]. 
Antimicrobial photodynamic therapy (aPDT) as a treatment modal-
ity is widely used to inactivate/reduce the microbial population [6,7]. 
The reports are available on the application of aPDT to combat viral 
infections [8–10]. aPDT involves the use of a non-toxic dye named 
photosensitizer and visible light of a specific wavelength in the presence 
of oxygen to produce the reactive photoproducts including reactive 
oxygen species (ROS) that can cause fundamental damage to viral 
structures which are involved in causing infection. [8,10–14]. 
Curcumin (Cur) is a natural polyphenol derived from the turmeric 
rhizomes (Curcuma longa L.) which have been reported to have a wide 
range of pharmacological effects including antiviral activity [15]. It has 
been demonstrated that the antimicrobial effects of Cur are potentiated 
by the presence of light (430–450 nm), and the phototoxicity is related 
to the generation of ROS. Unfortunately, Cur evidences different prob-
lems for its clinical application, including extremely poor oral 
bioavailability, low-aqueous solubility, inadequate tissue absorption, 
and rapid systemic clearance [16]. To overcome these drawbacks, 
different delivery systems and strategies such as nano-encapsulation of 
Cur in poly (lactic-co-glycolic acid) (PLGA) have been investigated [17, 
18]. PLGA, a copolymer of polylactic acid and polyglycolic acid, has 
been approved by the US Food and Drug Administration for biomedical 
and pharmaceutical applications [17]. 
Many studies have been done on PLGA as a drug carrier [18–21]. One 
of the drug delivery methods that has attracted the attention of re-
searchers in recent years is the electrospray method. This method 
promises to encapsulate the drug effectively and allowing for excellent 
control of the microsphere architecture [18]. The polyphenol Cur is 
applied in many critical conditions such as inflammatory and oxidative 
conditions, metabolic syndrome, anxiety, etc. [20]. 
Recently, several clinical trials describe the use of aPDT as an adju-
vant therapy which is defined as additional treatment given after the 
primary/ main treatment against viral infections, to make the primary 
treatment more likely to be successful. [22–24]. Many reports have also 
emerged over the years of the use of aPDT as an effective methodology 
for sterilization of blood or blood products [28–31]. 
Plasma contains important components including dissolved proteins 
(e.g., albumins, and globulins), and clotting factors. Plasma quality is 
currently assessed in vitro, using coagulation assays, measurements of 
total protein, and determination of levels of blood group antibodies (A 
and B) [28–30]. One-stage coagulation tests including prothrombin time 
(PT) and activated partial thromboplastin time (APTT) are the most 
widely used tests to investigate coagulation disorders. The PT test is used 
to monitor specifically the quantity and quality of the plasma coagula-
tion factors VII, V, and X, fibrinogen, and prothrombin. A prolonged PT 
reveals a decrease in the quantity and quality of the mentioned factors. 
The activated partial APTT is a test performed to investigate bleeding 
abnormalities specifically the missing or defective of the intrinsic 
(Factors XII, XI, VIII, IX) and common clotting pathways [28]. The 
importance of the measurement anti-A and anti-B is hemagglutinins in 
the serum originates from the universality of its antibodies. It has been 
revealed that the levels of anti-A and/or anti-B antibodies appear to be 
influenced mainly by interfering factors and determination of their 
levels (titers) and reactivity are the main indicator of plasma quality 
[29]. The content of total plasma proteins is another main indicator 
mentioned in the quality requirement of plasma. In order to fully un-
derstand the quality of treated plasma, it should be evaluated the con-
tent of total plasma proteins [29]. 
Nevertheless, no research has yet been reported to show the effects of 
aPDT on SARS-CoV-2 using Cur@PLGA-NPs. This study aimed to eval-
uate the photoelimination effects of Cur@PLGA-NPs plus blue laser light 
against the plasma samples containing SARS-CoV-2 in Vero cells. 
Furthermore, to verify whether the quality requirement of aPDT-treated 
plasma is suitable, the current study was conducted to investigate the 
differences of the levels of clotting factors, total plasma proteins, and 
anti-A and/or anti-B antibodies titrations in plasma of patient before and 
after aPDT treatment. 
2. Materials and methods 
2.1. Patient selection 
This study was approved by the Ethics Commission of Tehran Uni-
versity of Medical Sciences, Tehran, Iran under protocol IR.TUMS.VCR. 
REC.1399.490. The study was outlined to the patients and all of them 
provided informed consent. The blood samples were collected from the 
patients suspected of having COVID-19 referred to Bouali Hospital, Is-
lamic Azad University (BHIAU), Tehran, Iran following inclusion 
criteria: demographic data, medical history, exposure history, symp-
toms, signs, and chest computed tomographic (CT) scans. The presence 
of SARS-CoV-2 was then confirmed by real-time reverse transcription- 
polymerase chain reaction (RT-PCR) assay. 
2.2. Plasma products 
After collecting the blood samples into vacutainer tubes containing 
~1.8 mg K2EDTA per mL blood, the tubes were inverted carefully 10 
times to mix blood and anticoagulant. Then, the samples were imme-
diately centrifuged at 1000–2000 RCF at room temperature for 10 min. 
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After centrifugation, the plasma was visible at the upper part of the 
blood sample. 
2.3. Detection of SARS-CoV-2 and determine the load of the virus by RT- 
PCR assay 
After collecting the plasma samples, RT-PCR assay was done to 
confirm the presence of SARS-CoV-2. The RNAs were extracted through 
the Trizol method from the plasma specimens. RNase-free DNase I 
treatment kit and a Revert Aid First-Strand cDNA Synthesis kit (both 
Thermo Fisher Scientific, Waltham, MA, USA) were used according to 
the manufacturer’s protocol for the elimination of genomic DNAs from 
extracted RNA sample and synthesis of the first-strand cDNA, respec-
tively. Open reading frame 1ab (ORF1ab) was tested during the RT-PCR 
assay. The primers ORF1ab -forward (5′ − CCCTGTGGGTTTTACACTTAA 
-3′), ORF1ab -reverse (5′-ACGATTGTGCATCAGCTGA-3′) were designed 
using Primer3 v. 4.0 (http://frodo.wi.mit.edu/primer3/). All reactions 
were performed on the Roche Light cycler® 96 Real-Time PCR under the 
following conditions: incubation at 50 ◦C for 15 min and 95 ◦C for 5 min, 
40 cycles of denaturation at 94 ◦C for 15 s, and extending at 55 ◦C for 45 
s. According to the National Institute for Viral Disease Control and 
Prevention (China) (http://ivdc.chinacdc.cn/kyjz/202001/t20200121 
_211337.html), a cycle threshold value (Ct-value), less than 37 was 
defined as a positive test result, and a Ct-value of 40 or more was defined 
as a negative test, required confirmation by retesting. 
2.4. Included patients 
Of the 32 patients suspected of having COVID-19 who hospitalized to 
BHIAU between July and August 2020, 27 patients were eventually 
diagnosed with the COVID-19 using SARS-CoV-2 RT-PCR and included 
in the current study. 
2.5. Synthesis of Cur@PLGA-NPs as a photosensitizer 
According to our previous study, Cur@PLGA-NPs was synthesized by 
the Electrospraying method [21]. Briefly, the mixture of dime-
thylformamide (DMF; Merck, Darmstadt, Germany) and chloroform 
(Merck, Darmstadt, Germany) with a volume ratio of 1–3 was selected as 
the solvent system. PLGA (with an inherent viscosity midpoint of 2.3 
dL/g; Purac corporation) was added to the solvent system to increase its 
concentration by 0.5 %w/w. After that, 2 mM Cur (Sigma-Aldrich, 
Steinheim, Germany) was poured into the viscous solution, and the 
mixing process continued for 24 h. After the homogenous solution was 
obtained, the electrospinning process for the preparation of nano-
particles began, as follows: 5 mL of the resulting solution was poured 
into a syringe equipped with a 22-gauge needle. The distance from the 
needle to the collector was set at 20 cm. Then, a voltage of 20 kV was 
applied to form nanoparticles on the collector, which was covered with 
aluminum foil. The flow rate was fixed on 2 mL/h, which is low enough 
to allow the solvent to evaporate completely, preventing secondary 
droplets. The process was performed at room temperature and the foil 
was placed in a vacuum dryer to remove any remaining solvent from the 
particles. Finally, the nanoparticles were extracted from the mentioned 
foil. The schematic diagram of Cur@PLGA-NLs synthesis is shown in 
Fig. 1. 
2.6. Characterization of the core-shell Cur@PLGA-NPs 
Morphology and particle size distribution were studied by the 
Scanning Electron Microscope (SEM; SERON AIS-2100, South Korea) 
analysis, the accelerating voltage was 15 kV. Particle size distribution 
was evaluated by ImageJ (image analyzer software developed by the 
National Institute of Health, USA). To further examine the morphology 
and core-shell structure of the nanoparticles, the Transmission Electron 
Microscope (TEM; Zeiss EM10C) test with an accelerating voltage of 80 
Kv, was performed. In addition, to investigate possible interactions be-
tween components, Fourier Transform Infrared (FTIR) spectroscopy 
analysis (Bomem, Canada) in a range of 400-4000 cm− 1 was done. 
2.7. Absorption spectra of Cur@PLGA-NPs 
The absorption spectra of synthesized Cur@PLGA-NPs was carried 
out by UV–vis spectrophotometer, scanning the absorbance spectra in 
the range of 300–600 nm wavelength. 
Fig. 1. The schematic diagram of Cur@PLGA-NLs synthesis.  
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2.8. Evaluation of drug loaded efficiency 
The percentage of Cur incorporated was determined by centrifuging 
the Cur@PLGA-NPs at 9000 rpm at room temperature for 30 min. The 
supernatant was then obtained to measure the absorbance at 425 nm 
using an UV–vis spectrophotometer. The encapsulation efficiency (EE) 
and the Cur loading capacity (LC) were determined using the following 
equations: 
EE% =
total amount of Cur − free Cur
total amount of Cur
× 100  
LC% =
total amount of Cur − free Cur
nanoparticles weight
× 100  
2.9. Physical stability of Cur@PLGA-NPs 
To evaluate shelf life, Cur@PLGA-NPs was stored in the containers at 
4 ◦C and 37 ◦C. According to the previous study [32], the particle size, 
polydispersity index, and zeta potential were assessed at different time 
intervals during storage for 30 days. 
2.10. Preparation of Vero cell line culture 
Normal African Green Monkey Kidney Epithelial Cells (Vero cell line; 
IBRC C10001) purchased from the Iranian Biological Resource Center 
(Tehran, Iran) was cultured in the Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 2 mM L-glutamine, 10 % fetal bovine serum 
(FBS), 100 μg/mL amphotericin B and 1% penicillin/streptomycin 
antibiotic solution (all purchased from Sigma-Aldrich, Steinheim, Ger-
many) and maintained in a humidified incubator at 37 ◦C with a 95 % air 
and 5% CO2 atmosphere. The medium was changed every 3–4 days. 
2.11. Light source 
A continuous blue laser (Laser Diode Stabilizer LDS201, Asha beam 
profile Co., Iran; Fig. 2) at the wavelength of 450 ± 10 nm with an 
output intensity of 1.6 W/cm2 was used as a light source. The output 
power at the optic tip was measured by a photodiode power meter (PMB- 
104 power meter, Asha beam profile Co., Iran). 
2.12. Experimental design 
2.12.1. Treatment of the plasma containing SARS-CoV-2 with a 
photosensitizer, blue laser light, and aPDT 
While the viral load is different in the Plasma of the patients with 
COVID-19, to correctly interpret the results of the current study, the 
viral load in the plasma samples of all patients was adjusted to the 
minimal viral load in plasma samples among patient by adding sterile 
plasma. 150 μL of plasma containing SARS-CoV-2 were added to the 
wells of a 96-well flat-bottom microtiter plate (JET BIOFIL®, Jet Bio- 
Filtration Co., Ltd, Guangzhou, China). Then, 150 μL of Cur@PLGA- 
NPs with different concentrations (3, 5, 7, 10, and 15 % wt.) were 
added to the wells in column one. In column two, the plasma was irra-
diated with a blue laser for 1, 3, and 5 min under the single wavelength 
of 450 ± 10 nm with energy densities of 104.5, 313.7, and 522.8 J/cm2, 
respectively. In the next columns, aPDT was performed so that after 5 
min of adding the non-cytotoxic highest concentration of Cur@PLGA- 
NPs to the plasma, the cells were exposed to the highest energy den-
sity of the blue laser light. All experiments were performed under the 
class III biological safety cabinet. 
2.12.2. Treatment of the Vero cell lines with a photosensitizer, blue laser 
light, and aPDT 
Similar to the above section, Vero cell lines were treated with a 
photosensitizer, blue laser light, and aPDT. Briefly, in the third subcul-
ture of Vero cells, a seeding density of 1.0 × 105 cells/well was placed in 
a flat-bottomed 96-well cell culture microplate and allowed to adhere for 
24 h at 37 ◦C in a CO2 incubator. After 24 h of incubation, Vero cells 
were then treated with different concentrations of Cur@PLGA-NPs, 
different times of blue laser light irradiation, and aPDT with the non- 
cytotoxic highest concentration of Cur@PLGA-NPs plus the highest en-
ergy density of the blue laser light. After 24 h incubation at 37 ◦C in a 
CO2 incubator, the cells were washed with sterile phosphate-buffered 
saline (PBS) to eliminate non-adherent cells. Finally, a 3-(4,5dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell prolifer-
ation assay kit (Sigma-Aldrich, Steinheim, Germany) was used based on 
the manufacturer’s instructions to evaluate the cell cytotoxicity using a 
microplate reader (Bio-Tek Instruments, USA) at 540 nm. 
2.13. Cell cytotoxicity assessment of treated Vero cell lines with treated 
plasma containing SARS-CoV-2 
About 1.0 × 105 cells/well were seeded to a flat-bottom 96-well 
microtiter plate and incubated at 37 ◦C in a CO2 incubator for 24 h. 
After the Vero cells grew into a single layer in a 96-well microtiter plate, 
the culture medium was discarded and the treated plasma with the non- 
cytotoxic highest concentration of Cur@PLGA-NPs (10 % wt.) and the 
highest energy density of the blue laser light (522.8 J/cm2) was added. 
After 24 h, the cell cytotoxicity of treated Vero cell lines was determined 
using the MTT cell proliferation assay kit at 540 nm. 
2.14. Estimation of the apoptotic effects in treated Vero cell lines with 
treated plasma containing SARS-CoV-2 
To estimate the apoptotic effects of treated plasma containing SARS- 
CoV-2 on Vero cells, about 1.0 × 105 cells/well were seeded to a flat- 
bottom 96-well microtiter plate and 150 μL of the treated plasma was 
added and incubated at 37 ◦C in a CO2 incubator for 24 h. The cells were 
then washed with PBS and divided into two equal parts for flow 
cytometry and fluorescent staining as follows: 
2.14.1. Detection of apoptosis by flow cytometry 
The washed cells were re-suspended in 100 μL 1x Annexin V-FITC 
binding buffer. Then, 5 μL Annexin V-FITC and 5 μL propidium iodide 
(PI) were added to each well and incubated at room temperature in dark 
for 15 min. All process was carried out according to the manufacturer’s 
instructions (BD Biosciences, San Diego, CA, USA). Finally, the percent 
of apoptotic cells was determined by flow cytometry and data were 
analyzed using ver-7 Flowjo software. Fig. 2. The blue laser device used in this study.  
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2.14.2. Detection of apoptosis by fluorescent staining 
Paraformaldehyde solution (4% in PBS) was added to fix the washed 
cells at room temperature for 30 min. The cells were then washed with 
PBS (pH 7.2) and stained with dual acridine orange (AO) /ethidium 
bromide (EB) fluorescent staining solution (100 μg/mL AO and 100 μg/ 
mL EB) for 10 min. The washed cells were seen under the fluorescent 
microscope (OLYMPUS BX53, Japan). 
2.15. Measures of plasma quality 
2.15.1. Coagulation assays 
PT and APTT measurements were performed using the coagulometer 
(Diagnostica STAGO, France; Fig. 3). PT and APTT tests use venous 
blood of patients which were decalcified using citrate ions to stop the 
clotting process. The plasma was separated from the blood cells by 
centrifugation at 4000 rpm for 20 min. The plasmas showing evidence of 
clot formation and/or hemolysis were discarded. The PT test was done 
by adding thromboplastin, to the patient’s plasma that converts pro-
thrombin to thrombin. After incubation of the mixtures in a water bath 
(37 ◦C) for one minute, the calcium chloride (CaCl2) was added to the 
mixtures to neutralize the sodium citrate and allow clotting to start. The 
PT test is timed from the addition of the CaCl2 until the plasma clots. 
This time is called PT. The PT within the 10− 15 s range shows that the 
patient has normal amounts of the clotting factors. In the APTT test 
calcium, kaolin, and cephalin were added to the plasma to start the 
intrinsic pathway of the coagulation cascade. Kaolin serves to activate 
the contact-dependent Factor XII and cephalin substitutes for platelet 
phospholipids. The APTT is the time it takes for clot formation. Nor-
mally, it takes within 22− 38 s. 
2.15.2. Determination of total protein 
Total plasma protein content was measured as described previously 
by the method of Bradford [33]. Briefly, Coomassie Brilliant Blue G-250 
(Sigma-Aldrich, Steinheim, Germany) was dissolved in 95 % ethanol 
(100 mg/50 mL). Then, 1 mL of 85 % H3PO4 was added under stirring, 
before distilled water was added to a total volume of 10 mL. The 
resulting solution was filtered through a filter paper and kept at 4 ◦C. 
Standard concentrations of bovine serum albumin (BSA) (Sigma-Al-
drich, Steinheim, Germany) was prepared with 0.15 M NaCl to final 
concentrations of 0 (blank = No protein), 25, 50, 100, and 200 μg/mL. 
Also, serial dilutions of the samples were prepared. 10 μL of each BSA 
concentrations was added to the separate well of the 96-well microplate. 
50 μL of Bradford solution was added to each well and mixed gently. 
After 5 min the microplate was read at 595 nm wavelength. The 
absorbance of the standards was plotted against their concentration. The 
concentrations of the samples were calculated using the standard curve 
of BSA. 
2.15.3. Titration procedure 
Anti-A and/or anti-B antibodies measurements were performed 
using a titration procedure as described previously [31]. Two-fold 
diluted patient’s plasma was incubated in plastic tubes at room tem-
perature with a 5% suspension of red blood cells (RBC) (A and B). 
Thereafter, the samples were centrifuged at 3000 rpm for 15 s to 
determine the highest titer where the RBC remained agglutinated after 
gentle shaking (Fig. 4). 
2.16. Statistical assessment 
Data were entered into the Statistical Package for Social Sciences 
(SPSS) version 23 and analyzed using one-way analysis of variance 
(ANOVA). The results were reported as mean ± standard deviation (SD) 
and P-values <0.05 were considered significant. 
3. Results 
3.1. Synthesized Cur@PLGA-NPs as the photosensitizing agent 
The size and morphology of Cur@PLGA-NPs were investigated by 
SEM analysis and the ImageJ program. As can be seen in Fig. 5a, the 
spherical morphology is dominant. The distribution of particles is 
acceptable visually. To examine the particle size distribution quantita-
tively, about 300 particles were chosen randomly and the size of them 
was measured. The TEM test was used to evaluate the dispersion of Cur 
in the polymeric particles to demonstrate the structure of the core-shell 
(Fig. 5b). The dark spots in Fig. 4b represent the Cur. According to the 
results, the EE and LC percentage of the Cur in Cur@PLGA-NPs were 
87.6 ± 3.25 % and 8.42 ± 0.23 %, respectively. 
The FTIR spectra of the neat Cur, neat PLGA, and core-shell nano-
particles are shown in Fig. 5c. The board characteristic peak at ~3480 
cm− 1 was corresponding to O–H vibration of the phenol, in the Cur 
spectrum. The peak at ~1628 cm− 1 was referred to as the carbonyl 
group. In addition, the peaks at 2963, 1430, and ~1376 cm− 1 are 
associated with the C–H stretching of methyl groups. The peaks at 
~1400− 1500 cm− 1 corresponded to the –C-O elongation of the 
Fig. 3. Semi-auto coagulation analyzer (coagulometer) used to test the coag-
ulation factors (PT and APTT). 
Fig. 4. Anti-A and/or anti-B antibodies measurements were performed using 
the titration procedure where the RBC remained agglutinated after 
gentle shaking. 
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hydroxyl group. The CH– bending of the alkene groups has represented 
the peaks in the range of 700− 900 cm− 1 [34,35]. Furthermore, there is 
another peak at 1602 cm− 1 that confirms the presence of aromatic rings 
[35]. 
The peaks of the mentioned polymer are located between 
2850− 3000 cm− 1 and 1451 cm− 1 which belong to the C–H of the methyl 
group. The C–O stretching has been characterized by a peak at ~1750 
cm− 1 [36]. Another peak for biopolymer spectra is located at 1081 
cm− 1that signifies the presence of C–O in PLGA and the C− CH3 vi-
brations are depicted by the shoulder. The peaks at ~870 and 1387 
cm− 1 can be related to O–H vibrations [36,37]. The FTIR spectra of 
Cur@PLGA-NPs indicated that all the peaks are present and the process 
seems to be the summation of the PLGA and Cur spectra, an indication of 
the intact molecular structure of primary components after blending and 
electrospraying. In brief, the electrospray method does not change the 
material’s nature. 
3.2. UV–vis spectra of Cur@PLGA-NPs 
The UV–vis spectrum of Cur@PLGA-NPs aqueous solution is pre-
sented in Fig. 6. As shown, the absorption spectrum of Cur@PLGA-NPs is 
a broadband with a maximum absorbance peak at a wavelength ~425 
nm, which could be assigned to low energy π–π* excitation of the Cur, as 
reported in Kim et al. [38]. This peak is typical for Cur. 
3.3. Physical stability of Cur@PLGA-NPs during storage 
Cur@PLGA-NPs stability was measured by particle size over 30 days 
at 4 ◦C and 37 ◦C, which showed no significant variation between day 
0 and day 30 (P > 0.05; Fig. 7). No significant changes were achieved in 
the polydispersity index (P > 0.05) and zeta potential (P > 0.05) during 
30 days at 4 ◦C and 37 ◦C, indicating that there was no aggregation. 
3.4. Confirmation of the presence of SARS-CoV-2 by detection of ORF1ab 
gene 
The amplification of ORF1ab gene in the synthesized cDNA template 
was confirmed the presence of SARS-CoV-2 (84.3 %). A 2% gel agarose 
and an amplification curve of samples for SARS-CoV-2 detection based 
on the ORF1ab gene were shown in Figs. 8a and b. 
3.5. Efficacy of photosensitizer, blue laser light, and aPDT on Vero cell 
lines 
To determine the maximum sub-cytotoxic effect of aPDT for treat-
ment of plasma containing SARS-CoV-2, the Vero cell cytotoxicity of 
different concentrations of Cur@PLGA-NPs alone, different energy doses 
of blue laser alone, and aPDT with several blue laser energy doses 
(104.5, 313.7, and 522.8 J/cm2) in combination with the different 
Cur@PLGA-NPs concentrations (3, 5, 7, 10, and 15 %) were investi-
gated. Different concentrations of Cur@PLGA-NPs (3, 5, 7, and 10 %) 
lonely had no effect on viable cells (1.5, 4.0, 5.8, 6.8, and 23.4 % 
reduction, respectively); it was nearly the same as the untreated control 
group. Increasing Cur@PLGA-NPs concentration further to 15 % caused 
a statistically significant cytotoxic effect (23.4 %) compared to the un-
treated control group (P < 0.05) and it was not the desired effect of 
Cur@PLGA-NPs (Fig. 9a). 
On the other hand, laser energy doses of 104.5, 313.7, and 522.8 J/ 
cm2 caused around 2.8, 4.7, and 10.9 % reduction in the viable cell 
count when applied alone, respectively (Fig. 9b). These energy doses 
alone did not cause any significant change in cell number (P > 0.05). 
Fig. 5. Characterization of the synthesized Cur@PLGA-NLs; a) SEM image of 
Cur@PLGA-NLs (scale bar represents 1 μm), b) TEM image of Cur@PLGA-NLs at 
different magnification, Left image with less magnification (scale bar represents 
250 nm), right with more magnification that shows the core-shell structure well 
(scale bar represents 20 nm), c) FT-IR spectra of PLGA (pink), Cur (yellow), 
Cur@PLGA-NLs (blue). 
Fig. 6. UV–vis absorption spectra of Cur@PLGA-NLs.  
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104.5 J/cm2 of light with 3, 5, 7, and 10 % of Cur@PLGA-NPs 
resulted in the statistically non-significant amount of cell reduction in 
all of the Cur@PLGA-NPs doses tested (5.4 %, 9.6 %, 12.3 %, and 14.7 % 
respectively; all P > 0.05). When all of the Cur@PLGA-NPs doses tested 
(3, 5, 7, and 10 %, respectively) were used with 313.7 J/cm2 of energy 
dose, there was almost no significant change in the number of viable 
cells compared to the untreated control group (8.1 %, 11.7 %, 15.9 %, 
and 17.1 %, respectively; all P > 0.05; Fig. 9c). An energy dose of 522.8 
J/cm2 did not cause any significant change in the viable cell count when 
applied with 3, 5, 7, and 10 % of Cur@PLGA-NPs (10.3 %, 14.2 %, 17.0 
%, and 19.9 % respectively; P > 0.05). Towards the end of this 
Cur@PLGA-NPs concentration range, the desired effect of aPDT 
following treatment of cell culture with maximum dosed of blue laser 
light (522.8 J/cm2) and 10 % of Cur@PLGA-NPs achieved by a non- 
significant decrease in the number of viable cells. The sub-cytotoxic 
effect of aPDT (10 % wt. Cur@PLGA-NPs plus 522.8 J/cm2 dose of 
Fig. 7. Measurement of physical stability of Cur@PLGA-NPs during storage using particle size, polydispersity index, and zeta potential of Cur@PLGA-NLs in different 
conditions; a) at 4 ◦C, b) at 37 ◦C. 
Fig. 8. Confirmation of the presence of SARS-CoV-2 by detection of ORF1ab gene: A) The cDNA template synthesized from ORF1ab on the 2% gel agarose: 1. Ladder 
50 bp, 2. Control positive (108 bp), 3 and 4. Two positive samples (108 bp). B) The amplification curves of positive samples: 1. Control positive, 2 and 3. Two 
positive samples. 
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blue laser light) was used for the treatment of plasma containing SARS- 
CoV-2. 
3.6. Determination of cell cytotoxicity of Vero cells with treated plasma 
containing SARS-CoV-2 
The Vero cells were infected with treated plasma by aPDT at the non- 
cytotoxic highest concentration of Cur@PLGA-NPs (10 % wt.) and the 
highest energy density of the blue laser light (522.8 J/cm2). The results 
of the viral cytotoxicity using the MTT assay were presented in Fig. 10. 
Based on the results of these experiments, it was found that there was 
significant cell reduction in treated Vero cells with treated plasma 
containing SARS-CoV-2 using 10 % wt. Cur@PLGA-NPs, as well as, blue 
laser light at an energy density of 522.8 J/cm2 alone by 52.2 % and 68.7 
%, respectively. Furthermore, treated plasma containing SARS-CoV-2 
with aPDT (10 % wt. Cur@PLGA-NPs plus blue laser light at 522.8 J/ 
cm2) did not cytotoxic effect on the Vero cell line (Fig. 10). 
3.7. Assessment of the apoptotic effects in treated Vero cells with treated 
plasma containing SARS-CoV-2 
To explore the effect of photosensitizer, blue laser light, and aPDT on 
Vero cell apoptosis, flow cytometry and fluorescent staining assays were 
performed in our investigation. Flow cytometry analysis demonstrated 
that exposure to plasma containing SARS-CoV-2 had a marked apoptotic 
effect (86.1 %) on Vero cells, with a complete decline in cell culture 
viability (Fig. 11a). Consistent with this observation in Figs. 11c and d, 
the results of flow cytometric analysis indicated a significant increase in 
the apoptotic population of treated Vero cells with Cur@PLGA-NPs and 
laser light alone (33.7 % and 49.3 %, respectively) compared with a 
control group (Untreated Vero cells). On the other hand, unlike infected 
Vero cells with plasma containing SARS-CoV-2 (Fig. 11b), considerable 
apoptotic effects were not observed in treated Vero cells with treated 
plasma containing SARS-CoV-2 by aPDT (Fig. 11e). 
In the fluorescent staining analysis, no significant apoptosis was 
observed in the Vero cells in the control groups (Fig. 12a). Apoptotic 
Vero cells, marked by AO/EB staining (nuclear yellow-green and orange 
color), were seen in treated Vero cells with plasma containing SARS- 
CoV-2 (Fig. 12b). The apoptotic effects of treated plasma containing 
SARS-CoV-2 with 10 % wt. Cur@PLGA-NPs on Vero cells were similar to 
those treated with blue laser light alone (Fig. 12c and d). As shown in 
Fig. 12e, no significant increase in the apoptotic population of treated 
Fig. 9. Determination of the Vero cells viability by MTT assay at 540 nm; I) Treated Vero cells with different concentrations of Cur@PLGA-NLs, II) Treated Vero cells 
with different irradiation times of blue laser light, and III) Treated Vero cells with aPDT using 10 % wt. Cur@PLGA-NPs plus blue laser light at an energy density of 
522.8 J/cm2. 
Fig. 10. Determination of the cell cytotoxicity of Vero cells with treated plasma 
containing SARS-CoV-2 by MTT assay at 540 nm; P: Untreated plasma con-
taining SARS-CoV-2, P*: Treated plasma containing SARS-CoV-2, PS: Photo-
sensitizer (10 % wt. Cur@PLGA-NPs), aPDT: 10 % wt. Cur@PLGA-NPs plus blue 
laser light at an energy density of 522.8 J/cm2. Significant differences ac-
cording to the control. 
* P < 0.05. 
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Vero cells with treated plasma containing SARS-CoV-2 by aPDT. 
3.8. Determination of PDT induced adverse effects on plasma quality 
The results of total plasma protein content, basic coagulation tests 
(PT and APTT), and anti-A and/or anti-B antibodies titers were showed 
in Table 1. Total plasma protein content, PT, APTT, and anti-A and/or 
anti-B antibodies titers showed no significant changes (P > 0.05 for all 
comparisons) in treated plasma as compared to untreated plasma. 
4. Discussion 
Many diagnostic tests for COVID-19 are available including RT-PCR, 
loop-mediated isothermal amplification (LAMP), lateral flow, and 
enzyme-linked immunosorbent assay (ELISA) [39,40]. Currently, 
RT-PCR assay, as a method for detecting the presence of specific genetic 
material even in low copy numbers, is used for detection of SARS-CoV-2 
in the nasopharyngeal swab, sputum, blood, and stool samples of pa-
tients [41]. Herein, the positive test results were determined based on 
the Ct-value less than 37 according to the IVDC. 
Recently, aPDT has emerged as a promising therapeutic approach for 
the treatment of different diseases. The antiviral activities of aPDT are of 
interest as an alternative tool in antiviral treatments [24–27]. Another 
aspect of photodynamic action of aPDT against viruses, currently 
attracting considerable interest, is no resistance to aPDT was reported 
[22]. Nucleic acids (DNA or RNA), virus proteins, and viral lipids are 
three principal molecular targets for aPDT. During aPDT, the photo-
sensitizing agent can cross the outer cover of viruses and intercalate into 
their DNA/RNA [42]. Antiviral activity of produced ROS under blue 
laser light irradiation has been shown [8]. 
Although there is no evidence specifically investigating the effect of 
aPDT on viral lipids and/or proteins, there are investigations about the 
effect of ROS on viral lipids [43–45]. Since there are viral lipids in the 
envelope of the SARS-CoV-2, it should probably be sensitive to the ef-
fects of aPDT. As an antiviral agent, Cur has been reported to play a 
potent role in the regulation of proliferation and apoptosis in various 
types of viral cells. The results of Maiti et al. [46] study suggested that 
Cur has potent inhibitory properties of growth for glioblastoma multi-
forme cells and can rapidly kill the malignant glioma cells via DNA 
fragmentation. As well as, Cur induced cell death due to excess pro-
duction of ROS. 
In this study, PLGA was used to overcome the poor bioavailability of 
Cur due to its low water-solubility. Electrical conductivity, polymer 
concentration, solvent system, and electrospinning process parameters 
affect the size and final morphology of obtained particles. So, these 
parameters were determined with high accuracy for achieving smaller 
Fig. 11. Determination of the apoptotic effects 
in treated Vero cells with treated plasma con-
taining SARS-CoV-2; A) The apoptotic ratio was 
assessed by flow cytometry with Annexin V 
staining in Vero cells: a. Untreated Vero cells 
(as a control group), b. Treated Vero cells with 
untreated plasma containing SARS-CoV-2, c) 
Treated Vero cells with treated plasma con-
taining SARS-CoV-2 using 10 % wt. Cur@PLGA- 
NPs, d) Treated Vero cells with treated plasma 
containing SARS-CoV-2 using blue laser light at 
an energy density of 522.8 J/cm2, e) Treated 
Vero cells with treated plasma containing 
SARS-CoV-2 using aPDT with 10 % wt. 
Cur@PLGA-NPs plus blue laser light at an en-
ergy density of 522.8 J/cm2. B) Percent of cell 
viability at 540 nm. P: Untreated plasma con-
taining SARS-CoV-2, P*: Treated plasma con-
taining SARS-CoV-2. PS: Photosensitizer (10 % 
wt. Cur@PLGA-NPs). Significant differences 
according to the control, * P < 0.05.   
M. Pourhajibagher et al.                                                                                                                                                                                                                       
Photodiagnosis and Photodynamic Therapy 34 (2021) 102286
10
particles [21]. 
As FTIR results showed, the addition of Cur to the system did not 
change the nature of that since the spectra of the nanoparticles indicated 
the summation of the PLGA and Cur spectra. 
Herein, the Vero cell was used as an appropriate cell line for COVID- 
19 propagation. To confirm the potential role of aPDT in Vero cell 
growth, MTT assay was performed to assess the cell viability after 
treatment with Cur@PLGA-NPs over a wide range of concentrations and 
different irradiation times of blue laser. Regarding the collected data, 
there were no significant changes in the viability of Vero cells after 
treatment with different concentrations of Cur@PLGA-NPs, irradiation 
times of blue laser light, as well as, aPDT. 
The most commonly used clinical application of the aPDT is 
currently the field of viral decontamination of blood products [24–27]. 
Recently, the inactivation of various viruses such as SARS-CoV-2 and 
MERS-CoV in plasma products using aPDT was investigated. Jin et al. 
[24] conducted aPDT with methylene blue (MB) as a photosensitizer 
that could be effective against SARS-CoV-2 in plasma without any side 
effects. According to the results, different concentrations of MB (1, 2, 
and 4 Mm) under the wavelength of 630 nm light for 2 min could 
completely inactivate the virus and the viral titer of SARS-CoV-2 
decreased to 4.5 log10 median tissue culture infectious dose 
(TCID50)/mL. As commented by Eickmann et al. [25,26], MB plus 
visible light at the light doses as low as 30 J/cm2, is capable to reduce 
SARS-CoV and MERS-Cov more than 3.1 and 3.3 log10 TCID50/mL in 
plasma, respectively. In another study by Keil et al. [27], the inactiva-
tion of the MERS-CoV was evaluated using a riboflavin-based and ul-
traviolet light-based photochemical treatment in plasma products. The 
mean reductions in the log titer of MERS-CoV for the pooled and indi-
vidual donor plasma were ≥ 4.07 and ≥ 4.42, respectively. 
According to the collected data from this study, there was a 
considerable cell degradation in the treated Vero cells with treated 
plasma containing SARS-CoV-2 using Cur@PLGA-NPs and blue laser 
light alone. In addition, cell degradation was not only observed during 
aPDT, but also the viability of treated Vero cells with treated plasma 
containing SARS-CoV-2 was similar to the untreated Vero cell (as a 
control group). Similar to the previous studies, aPDT could significantly 
reduce the titer of SARS-CoV-2 in plasma without damaging the Vero 
cells [25–27]. There were no significant changes in the anticoagulation 
factors (PT and APTT), total plasma protein content, and anti-A and/or 
anti-B antibodies titers between before and after aPDT treatment, thus 
indicating no adverse effects on plasma quality in aPDT-exposed plasma 
which could induce the inactivation of SARS-CoV-2 contaminants. 
Results suggested that a higher concentration of Cur@PLGA-NPs and 
time of light irradiation-induced apoptotic activity by annexin-V/PI 
staining in the treated Vero cells with treated plasma containing 
SARS-CoV-2. Also, the apoptotic activities of Cur@PLGA-NPs and blue 
laser were significantly higher than aPDT and control groups. Based on 
the data obtained, it could be concluded that aPDT exhibited in vitro 
anti− COVID-19 activities without induction of apoptosis and destruc-
tion of Vero cells. 
Fig. 12. Determination of the apoptotic effects 
in exposed Vero cells by acridine orange 
/ethidium bromide fluorescent staining under 
the fluorescent microscope (OLYMPUS BX53, 
Japan; objective magnification 10x; Scale 
bars=100 μm): a) Untreated Vero cells, as a 
control group, revealing green nuclear staining, 
b) Exposed Vero cell culture with untreated 
plasma containing SARS-CoV-2 showing a large 
number of apoptotic cells which had orange 
and red nuclear fluorescence emission, c) 
Exposed Vero cell culture with treated plasma 
containing SARS-CoV-2 using 10 % wt. 
Cur@PLGA-NPs, indicating decrease in cells 
with orange-red nuclear staining in comparison 
to exposed Vero cell culture with untreated 
plasma containing SARS-CoV-2, d) Exposed 
Vero cell culture with treated plasma contain-
ing SARS-CoV-2 using blue laser light (522.8 J/ 
cm2) representing increase the number of 
apoptotic cells more than exposed Vero cells 
with treated plasma containing SARS-CoV-2 
using 10 % wt. Cur@PLGA-NPs and less than 
exposed Vero cells with untreated plasma con-
taining SARS-CoV-2, e) Exposed Vero cells with 
treated plasma containing SARS-CoV-2 using 
aPDT with 10 % wt. Cur@PLGA-NPs plus blue 
laser light (522.8 J/cm2) demonstrating a sig-
nificant reduction in the number of apoptotic 
cells in comparison to exposed Vero cells with 
untreated plasma containing SARS-CoV-2.   
Table 1 
The total plasma protein content, PT, APTT, and anti-A and/or anti-B antibodies 











≥ 50 68.5 ± 4.3 63.1 ± 5.7 <0.001 
PT 10− 15 12.8 ± 1.7 13.9 ± 1.4 <0.001 
APTT 22− 38 31.3 ± 3.9 33.4 ± 5.4 <0.001 
anti-A min : max 
16 : 512     
<128 – 92.6 % 92.6 % <0.001 
<32 – 11.1 % 14.8 % <0.001 
anti-B min : max 
16 : 1024     
<128 – 89.9 % 92.9 % <0.001 
<32 – 18.5 % 18.5 % <0.001  
# Data of PT, APTT, and Total plasma protein are presented as mean ± SD. 
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5. Conclusion 
Our data support that aPDT (10 % wt. Cur@PLGA-NPs in combina-
tion with blue laser light at 522.8 J/cm2) exhibited in vitro anti− COVID- 
19 activity without the cytotoxic effects in Vero cells culture by a treated 
plasma containing SARS− COV-2. However, further in vivo animal and 
clinical trial studies are needed to confirm the effect of aPDT 
(Cur@PLGA-NPs in combination with blue laser light) on plasma 
clearance of SARS-CoV-2. Our study also clearly revealed that the 
quality of aPDT-exposed plasma is not significantly influenced by aPDT 
based on Cur@PLGA-NPs. 
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